Welcome to our dedicated page for INTEST SEC filings (Ticker: INTT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on INTEST's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into INTEST's regulatory disclosures and financial reporting.
INTEST CORP director Jeffrey A. Beck received an award of 12,000 shares of common stock. The grant was recorded at no cash cost per share and represents a compensation-related acquisition rather than an open-market purchase. After this grant, Beck directly holds 79,500 shares of INTT common stock.
INTEST CORP reported a proposed sale of Common Stock on a Form 144. The filing lists a broker-dealer (Citigroup Global Markets, Inc.) and a Restricted Stock Aware Vesting entry showing 6,460 shares. It also discloses two recent sales by Grant Richard N. Jr: 1,097 shares on 03/09/2026 for $14,618.51 and 1,397 shares on 03/11/2026 for $19,786.97.
inTEST Corporation provides an overview of its business for the year ended December 31, 2025, highlighting a diversified test and process technology portfolio across semiconductor, Auto/EV, Defense/Aerospace, Industrial, Life Sciences and Safety/Security markets. About 68% of 2025 revenue, or $77.9 million, came from markets outside semiconductor, reflecting progress on its VISION 2030 diversification strategy.
The company completed the acquisition of Alfamation S.p.A. for a total purchase price of $21.9 million, expanding automotive and specialty consumer electronics test capabilities and adding a related-party facility lease in Italy. It also consolidated Videology’s Netherlands operations into Massachusetts, incurring $0.8 million in severance charges and expecting about $0.3 million of remaining lease costs.
Backlog grew to $53.9 million at December 31, 2025, up from $39.5 million a year earlier, and inTEST ended the year with 407 employees. The filing also describes segment structures, key products, competitive landscape, acquisition and growth risks, supply chain exposure, AI and cybersecurity risks, and details of its $3.8 million debt with M&T Bank and related covenant waivers.
INTEST CORP President & CEO Richard N. Grant Jr. reported open-market sales of company common stock that were used to cover taxes on vesting restricted stock. He sold 1,397 shares at $14.1639 per share and 1,097 shares at $13.3259 per share pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2023. After these transactions, he holds 186,722 common shares directly and maintains multiple employee stock option awards, including options expiring between 2031 and 2035 with exercise prices ranging from $7.7400 to $16.0600.
INTEST CORP Division President–Electronic Test, Joseph Richard McManus Jr., reported tax-related share withholdings rather than open-market trades. On March 6 and 8, 2026, a total of 333 shares of common stock were withheld at $13.24 per share to cover tax obligations on vesting restricted stock. After these transactions, he directly holds 30,919 shares of common stock. He also retains multiple employee stock options, including grants exercisable at $7.74, $8.14, $11.33, $13.13, and $16.06 per share with expirations between 2031 and 2035, several of which vest in equal annual installments.
INTEST CORP division president Richard B. Rogoff reported routine share dispositions to cover taxes on equity compensation. On March 6 and March 8, 2026, a total of 291 shares of common stock were withheld at $13.24 per share to satisfy tax withholding obligations on vesting restricted stock.
After these tax-withholding dispositions, Rogoff directly holds 6,787 shares of common stock. He also holds equity awards that may convert into additional shares, including 4,040 restricted stock units that vest in four equal annual installments starting on March 17, 2026, and several stock option grants covering underlying common shares at exercise prices between $7.74 and $16.06 with expirations from 2032 through 2035.
inTEST Corp division president Michael F. Goodrich reported a routine tax-related share disposition. On March 6, 2026, 148 shares of common stock were withheld at $13.24 per share to cover tax obligations on the vesting of restricted stock, rather than sold in the open market.
Following this withholding, Goodrich directly holds 19,685 shares of inTEST common stock. He also retains employee stock options to buy additional shares, including options with an exercise price of $7.74 per share expiring on March 16, 2035 and options at $11.33 per share expiring on March 5, 2034, which vest in four equal annual installments starting in 2025 and 2026.
inTEST Corporation detailed 2026 compensation decisions for its President and CEO, Richard N. Grant, Jr., and its CFO, Treasurer and Secretary, Duncan Gilmour. Their base salaries will remain at 2025 levels of $428,915 for the CEO and $282,500 for the CFO.
The Compensation Committee set short-term performance bonus targets for 2026 at 85% of base salary for the CEO and 65% for the CFO, with actual payouts ranging from zero to above target depending on 2026 performance. The Committee also approved long-term incentive awards with grant date fair values of $600,000 for the CEO and $250,000 for the CFO, split equally among four-year time-vesting stock, a three-year performance-vesting award, and stock options.
The equity grants will be made on the second business day after the company files its 2025 Form 10-K, with options and time-based awards vesting in equal annual installments over four years. Performance-vested awards will cliff-vest after the period ending December 31, 2028, based on the company’s enterprise value as determined by the Compensation Committee, and all awards are issued under the inTEST Corporation 2023 Stock Incentive Plan.
INTEST CORP Division President–Electronic Test Joseph Richard McManus Jr. reported a disposition of 2,076 shares of common stock on March 4, 2026, recorded as a “Disposition to issuer” at a price of $0.00 per share. A footnote explains these shares were forfeited under the terms of his performance-based restricted stock award granted on March 8, 2023. After this forfeiture, he directly holds 31,252 common shares. The filing also updates his employee stock option positions, showing several option grants that vest in four equal annual installments beginning on March 17, 2026, March 6, 2025, March 8, 2024, and April 28, 2023, plus one option grant that is fully vested as of the report date.
inTEST Corp CFO Duncan Gilmour reported the disposition of 4,670 shares of common stock to the company on March 4, 2026. The shares were forfeited under a performance-based restricted stock award granted on March 8, 2023. After this, he directly holds 56,434 common shares, several employee stock options that vest in four equal annual installments beginning on March 9, 2023, March 8, 2024, March 6, 2025 and March 17, 2026, and 200 common shares held indirectly by his spouse.